HK1053262A1 - Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance. - Google Patents

Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance.

Info

Publication number
HK1053262A1
HK1053262A1 HK03104297A HK03104297A HK1053262A1 HK 1053262 A1 HK1053262 A1 HK 1053262A1 HK 03104297 A HK03104297 A HK 03104297A HK 03104297 A HK03104297 A HK 03104297A HK 1053262 A1 HK1053262 A1 HK 1053262A1
Authority
HK
Hong Kong
Prior art keywords
tolerance
treatment
glutamate receptor
metabotropic glutamate
dependance
Prior art date
Application number
HK03104297A
Other languages
English (en)
Inventor
Mauro Corsi
Francois Conquet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9887294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1053262(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1053262A1 publication Critical patent/HK1053262A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
HK03104297A 2000-03-09 2003-06-16 Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance. HK1053262A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0005700.0A GB0005700D0 (en) 2000-03-09 2000-03-09 Therapy
PCT/GB2001/001058 WO2001066113A1 (en) 2000-03-09 2001-03-09 Metabotropic glutamate receptor antagonists for treating tolerance and dependency

Publications (1)

Publication Number Publication Date
HK1053262A1 true HK1053262A1 (en) 2003-10-17

Family

ID=9887294

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104297A HK1053262A1 (en) 2000-03-09 2003-06-16 Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance.

Country Status (17)

Country Link
US (1) US20030195139A1 (zh)
EP (1) EP1267869B1 (zh)
JP (1) JP2003525902A (zh)
CN (1) CN1427720A (zh)
AT (1) ATE267013T1 (zh)
AU (1) AU783869B2 (zh)
CA (1) CA2402341A1 (zh)
DE (1) DE60103384T2 (zh)
DK (1) DK1267869T3 (zh)
ES (1) ES2220727T3 (zh)
GB (1) GB0005700D0 (zh)
HK (1) HK1053262A1 (zh)
NZ (1) NZ521228A (zh)
PT (1) PT1267869E (zh)
SE (1) SE1267869T5 (zh)
TR (1) TR200401862T4 (zh)
WO (1) WO2001066113A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024150A2 (en) * 2002-09-10 2004-03-25 Novartis Ag Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression
EP1874353A1 (en) 2005-04-05 2008-01-09 Yale University Glutamate modulating agents in the treatment of mental disorders
WO2006121919A2 (en) * 2005-05-05 2006-11-16 Massachusetts Institute Of Technology Methods of treating obsessive compulsive disorder
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007035823A2 (en) * 2005-09-20 2007-03-29 Molecular Neuroimaging, Llc Partial mglur5 antagonists and methods of use thereof
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2670116C (en) 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
US20130123254A1 (en) * 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
CA3066711A1 (en) * 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
AU2021404023A1 (en) * 2020-12-14 2023-06-29 Novartis Ag Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5543698A (en) * 1994-09-27 1996-08-06 Allen-Bradley Company, Inc. Method and apparatus used with AC motor for detecting unbalance
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
WO1998040407A1 (en) * 1997-03-14 1998-09-17 Johns Hopkins University Synaptic activation protein compositions and method
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
IL142047A0 (en) * 1998-10-02 2002-03-10 Sibia Neurosciences Inc Mglur5 antagonists for the treatment of pain and anxiety
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
EP1183238A1 (en) * 1999-05-17 2002-03-06 Eli Lilly And Company Metabotropic glutamate receptor antagonists
US6666209B2 (en) * 2001-02-20 2003-12-23 3M Innovative Properties Company Method and system of calibrating air flow in a respirator system

Also Published As

Publication number Publication date
EP1267869B1 (en) 2004-05-19
GB0005700D0 (en) 2000-05-03
AU3763401A (en) 2001-09-17
ES2220727T3 (es) 2004-12-16
NZ521228A (en) 2004-04-30
EP1267869A1 (en) 2003-01-02
SE1267869T5 (zh) 2004-09-07
ATE267013T1 (de) 2004-06-15
SE1267869T3 (zh) 2004-08-31
PT1267869E (pt) 2004-10-29
DK1267869T3 (da) 2004-09-20
CA2402341A1 (en) 2001-09-13
DE60103384T2 (de) 2005-06-16
AU783869B2 (en) 2005-12-15
TR200401862T4 (tr) 2004-10-21
JP2003525902A (ja) 2003-09-02
US20030195139A1 (en) 2003-10-16
WO2001066113A1 (en) 2001-09-13
CN1427720A (zh) 2003-07-02
DE60103384D1 (de) 2004-06-24

Similar Documents

Publication Publication Date Title
HK1053262A1 (en) Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance.
DK0901374T3 (da) Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
DE60205776D1 (en) Indolinon-derivative als protein-kinasehemmer
MX9603845A (es) Profarmacos de antagonistas del receptor de morfolino-taquiquinina.
SG167664A1 (en) 2,4-pyrimidinediamine compounds and their uses
MXPA06001008A (es) Derivados de 3-amino croman y 2-amino tetralina.
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
MXPA04004714A (es) Derivados de aril 1,4-pirazina sustituidos.
ATE328874T1 (de) Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
MXPA03007140A (es) Derivados de carbolina.
DE60020595D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
MXPA03009750A (es) Compuestos quimicos.
MXPA03010586A (es) N-[(1s)-1,2,3,4-tertrahidro-1-naftalenil benzamidas trisubtituidas, las cuales inhiben receptores que contienen p2x2/3.
DE60023025D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
BG105256A (en) Muscarinic agonists and antagonists
DE60015599D1 (de) 3,4-DIHYDRO-(1H)CHINAZOLIN-2-ON-VERBINDUNGEN ALS CSBP/p38-KINASE-INHIBITOREN
DE60140530D1 (de) 5-ht7 rezeptor-antagonisten
NZ335052A (en) Piperazino derivatives as neurokinin antagonists
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
AU2002322396A1 (en) 1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists
AP2000001963A0 (en) Paroxetine ascorbate.
DK1366033T3 (da) Kemiske forbindelser
MXPA03003926A (es) Amidas de alquinilo y sus aplicaciones terapeuticas.
UA51054A (uk) Спосіб лікування післяінсультних порушень і пристрій для його реалізації
MXPA04001166A (es) Usos de citocina de mamifero; reactivos relacionados.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090309